摘要
目的分析氟喹诺酮类抗菌药物联合哌拉西林钠他唑巴坦钠治疗社区获得性肺炎(CAP)患者的临床效果。方法选取2018年3月至2019年9月本院收治的CAP患者78例,按随机数字表法分为联合用药组与单一用药组,每组39例。单一用药组予以哌拉西林钠他唑巴坦钠治疗,联合用药组在单一用药组基础上予以氟喹诺酮类抗菌药物治疗。比较两组临床疗效、临床症状改善时间、病原菌清除率及治疗前后T淋巴细胞亚群(CD4^(+)、CD8^(+))水平。结果联合用药组治疗总有效率为94.87%,明显高于单一用药组的74.36%(P<0.05)。联合用药组发热消失时间、肺部阴影吸收时间、血常规恢复时间、痰液颜色改变时间均短于单一用药组(P<0.05)。治疗前,两组CD4^(+)、CD8^(+)水平比较差异无统计学意义;治疗后,联合用药组CD~4+水平高于单一用药组,CD8^(+)水平低于单一用药组(P<0.05)。联合用药组病原菌清除率为90.48%,明显高于单一用药组的70.73%(P<0.05)。结论氟喹诺酮类抗菌药物联合哌拉西林钠他唑巴坦钠治疗CAP效果显著,可调节患者免疫功能,改善临床症状,提高病原菌清除率,值得临床推广应用。
Objective To analyze the clinical effect of fluoroquinolone antibiotics combined with piperacillin sodium and tazobactam sodium in the treatment of patients with community-acquired pneumonia(CAP).Methods 78 CAP patients admitted to our hospital from March 2018 to September 2019 were selected and divided into combined medication group and single medication group according to random number table,with 39 cases in each group.The single medication group was treated with piperacillin sodium and tazobactam sodium,and the combined medication group was treated with fluoroquinolone antibacterial drugs on the basis of the single medication group.The clinical efficacy,clinical symptom improvement time,pathogen clearance rate,and T lymphocyte subsets(CD4^(+),CD8^(+))levels before and after treatment were compared between the two groups.Results The total effective rate of treatment in the combined medication group was 94.87%,which was significantly higher than the 74.36%in the single medication group(P<0.05).The time of fever disappearance,lung shadow absorption time,blood routine recovery time,and sputum color change time in the combined medication group were shorter than those in the single medication group(P<0.05).Before treatment,there was no significant difference in the levels of CD4^(+)and CD8^(+)between the two groups;after treatment,the CD4^(+)level of the combined medication group was higher than that of the single medication group,and the CD8^(+)level was lower than that of the single medication group(P<0.05).The clearance rate of pathogenic bacteria in the combined medication group was 90.48%,which was significantly higher than 70.73%in the single medication group(P<0.05).Conclusion Fluoroquinolone antibacterial drugs combined with piperacillin sodium and tazobactam sodium are effective in the treatment of CAP,which can regulate the immune function of patients,improve clinical symptoms,and increase the clearance rate of pathogenic bacteria.It is worthy of clinical application.
作者
李翀
LI Chong(Department of Breath Internal Medicine,Guixi People’s Hospital,Yingtan,Jiangxi,335400,China)
出处
《当代医学》
2021年第18期82-84,共3页
Contemporary Medicine
关键词
氟喹诺酮类抗菌药物
哌拉西林钠他唑巴坦钠
社区获得性肺炎
病原菌清除率
免疫功能
Fluoroquinolone antibacterial drugs
Piperacillin sodium and tazobactam sodium
Community-acquired pneumonia
Pathogen clearance rate
Immune function
